Loading Events
Find Events

Event Views Navigation

Upcoming Events › Grant

Events List Navigation

June 2017

Cycle 2: NIH Academic Research Enhancement Award (R15)

June 25

Sponsor: National Institutes of Health
Due Date: June 25, 2017 by 5 pm local time of applicant organization
Award: Direct costs limited to $300,000 over a maximum of 3 years.

Find out more »

HHMI Investigator Program

June 27

Sponsor: Howard Hughes Medical Institute
Due Date: June 27, 2017, 3 p.m. EDT
Award: Each investigator receives his or her full salary, benefits, and a research budget from HHMI. Appointment is for a seven-year term, which may be renewed after an exacting review process.

Find out more »
July 2017

Cycle 1: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3)

July 10

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 10, 2017
Due Date: August 9, 2017
Award: Actual needs; applicants may seek up to one year of UG3 funding. The UH3 phase cannot exceed four years.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

July 10

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 10, 2017
Application Due Date: August 9, 2017
Award: Actual needs; applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II.

Find out more »

Cycle 7: NINDS CREATE Bio Discovery Track: Optimization in Preparation for Development of Biotechnology Products and Biologics (U44)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017
Award: Budget not limited but must reflect the actual needs of project. Phase I costs will normally remain under $500,000 over up to 1 year; Phase II will normally remain under $2,000,000 over up to 3 years.

Find out more »

Cycle 7: NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017 by 5 pm local time of applicant
Award: Budgets are not limited but have to reflect the actual needs of the proposed project. UH2 phase should rarely exceed 1M per year and UH3 phase should rarely exceed 1.5M per year.

Find out more »

Cycle 7: NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017
Award: Actual needs should rarely exceed $1,000,000 in total cost per year during the Phase 1 and $1,500,000 in total costs per year during the Phase 2. 2 years for Phase I and up to 3 years for Phase II.

Find out more »

Cycle 2: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes

July 25

Sponsor: Patient-Centered Outcomes Research Institute
LOI Due Date: July 25, 2017
Application Due Date: October 25, 2017
Award: Research Award. The past cycle had direct costs of $10 million.

Find out more »

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 31

LOI DUE JULY 31, 2017
Preclinical Drug Discovery
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
Seeks to fund biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials. Up to $1.5 million.
Biomarkers Development
Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer’s disease, related dementias, and cognitive aging. $150,000-$300,000/year, 1-2 years.
Prevention Beyond the Pipeline
The ADDF seeks to support prevention drug discovery not covered by most research funders or our current RFPs. Funding can range from $50,000-$100,000 for epidemiological analyses, $150,000-$600,000 for preclinical research, and up to $1.5 million for clinical trials.
Accelerating Drug Discovery for Frontotemporal Degeneration
Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration. Funding can range from $100,000-$150,000 per year, average one year duration.

Find out more »
August 2017

Foundation for Physical Therapy

August 3

DUE AUGUST 3, 2017, NOON EDT
Foundation Research Grant
Funds clinically relevant research by emerging investigators seeking to evaluate the effectiveness of physical therapy interventions. This grant will provide $40,000 for either one or two year projects.
Snyder Research Grant
One $40,000 SRG is to be awarded to support relevant clinical research projects aimed to investigate: a) those services delivered by physical therapists; and b) the development of new interventions that offer reasonable assurance that they will be clinically relevant and therapeutically effective.

Find out more »

Cycle 2: Ruth L. Kirschstein National Research Service Awards (F Series)

August 8

Sponsor: National Institutes of Health
Due Date: August 8, 2017
Award: Fellowship

Find out more »

Cycle 2: Conference Grants (R13) and Conference Cooperative Agreements (U13)

August 12

Sponsor: NIH
Due Date: August 12, 2017
Award: Funding for conferences

Find out more »
September 2017

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Money, property, or both to an eligible entity to carry out an approved project or activity. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R41/R42)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Money, property, or both to an eligible entity to carry out an approved project or activity. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 3: Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)

September 5

Sponsor: NIH
LOI Due Date: September 5, 2017
Due Date: October 5, 201 by 5 pm local time of applicant
Award: Budgets for direct costs of up to $499,999 per year may be requested. Project period may not exceed 5 years.

Find out more »

Cycle 3: High Throughput Screening (HTS) to Discover Chemical Probes (R01)

September 5

Sponsor: National Institutes of Health
LOI Due Date: September 5, 2017
Application Due Date: October 5, 2017
Award: Actual needs 3 years

Find out more »

Cycle 1: Small Business Innovation Research (SBIR)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017
Award: Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III

Find out more »

Cycle 1: Small Business Technology Transfer (STTR)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017
Award: Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III

Find out more »
+ Export Events